Modulation of the immune response to tumors by a novel synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl] phenyl] acetamide (CL 259, 763)

• Published in: Cancer Immunology Immunotherapy 1986-05, Vol.22 (1), p.8-14
• Main Authors: SANG WANG, B, RUSZALA-MALLON, V, WALLACE, R. E, CITARELLA, R. V, YANG-I LIN, DURR, F. E
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - pharmacology; Animals; Anthraquinones - pharmacology; Antineoplastic Agents - pharmacology; Biological and medical sciences; Cell Line; Colony-Stimulating Factors - biosynthesis; Immunomodulators; Interleukin-1 - biosynthesis; Interleukin-2 - biosynthesis; Leukemia L1210 - immunology; Leukemia P388 - immunology; Lymphocyte Culture Test, Mixed; Macrophage Activation - drug effects; Medical sciences; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Mitoxantrone; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - immunology; Original; Pharmacology. Drug treatments; Plasmacytoma - immunology; Sulfones - pharmacology; T-Lymphocytes, Cytotoxic - drug effects; T-Lymphocytes, Regulatory - drug effects
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/BF00205710

CL 259,763, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide, is an orally active compound capable of modifying the reactivity of certain lymphoid cell populations affected by the growth of a tumor. The compound augmented the response of lymphocytes from tumor-primed animals to syngeneic tumor cells, resulting in a marked increase in tumor cell destruction. Likewise, it enhanced macrophage inhibitory effects on the growth of tumor cells in vitro. These "activated" macrophages were detectable in peritoneal exudates of treated mice 4 to 12 days after receiving a single oral dose of CL 259,763, with peak activity being demonstrable by day 7. The compound also restored the alloreactivity of lymphocytes from immunodepressed mice bearing the Lieberman plasma cell tumor, possibly by interfering with suppressor cells. Macrophages and lymphocytes from treated mice released significantly more IL-1 and IL-2-like factors in culture than did the control counterparts. Sera from treated mice also possessed more colony stimulating factor than those from normal mice. Immunoadjuvant effects were evident when the compound was administered with an inactivated L1210 leukemia vaccine and it enhanced the effectiveness of cytotoxic chemotherapy when given to mice challenged with P388 murine leukemia. These immunomodulating effects of CL 259,763 may hopefully be exploited in efforts to augment the immune response of the host to a progressively growing tumor.